after the court upheld the patent of the superior version of Xtandi, ARN509, to the original inventor, Dr Sawyers at UCLA. JNJ paid Dr.Sawyers just $1B, for the advanced version of Xtandi and even a 3rd version.
The original inventor of Xtandi now works for JNJ. Medivation missed their chance and could be wiped out after ARN509, now in Phase 3 approval,receives marketing approval.
Wrong. JNJ wouldn't have bought Aragon for $1B if they didn't own the rights to the advanced form of Xtandi, that is ARN509. Dr. Sawyers, the inventor of Xtandi at UCLA, gets a 10% royalty from Xtandi sales. He owns Aragon which is now JNJ. The research at a university never stops and new and improved versions of Xtandi will be coming out. Medivation bought a moment in time - that;s it.